Semaglutide vs. Tirzepatide: Which Is Right for You?

Semaglutide and tirzepatide are the two most-searched weight loss medications in the US — together pulling close to a million Google searches per month. Both are GLP-1 class peptides. Both produce meaningful weight loss. And both are available through physician prescription at Beverly Hills Rejuvenation Center.

But they are not the same drug, they don’t work the same way, and for most patients one is clearly the better choice. This guide breaks down the clinical differences, the trial data, who belongs on each protocol, and how BHRC approaches GLP-1 prescribing in 2026. If you’re newer to peptide therapy broadly, our beginner’s guide to peptides covers the full landscape first.

What Are Semaglutide and Tirzepatide — and How Do They Work?

The core difference is the receptor target. Semaglutide is a single-agonist — it activates the GLP-1 receptor. Tirzepatide is a dual-agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GIP component adds meaningful effects on insulin sensitivity and fat metabolism that GLP-1 alone doesn’t produce, which is why tirzepatide consistently outperforms semaglutide on weight loss metrics in clinical trials.

Semaglutide vs. Tirzepatide — What the Clinical Trials Show

The headline finding: in every major trial comparing the two, tirzepatide produces more weight loss. The SURPASS-6 trial — a direct head-to-head — showed tirzepatide produced significantly greater HbA1c reduction and weight loss versus semaglutide. This isn’t subtle. Tirzepatide is meaningfully more effective for most patients.

The caveat: semaglutide has a longer track record and the SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in patients with obesity and established cardiovascular disease — data that doesn’t yet exist for tirzepatide. For patients with cardiovascular history, this matters.

Which One Is Right for You — How BHRC Decides

Most patients: Start with tirzepatide

If you’re coming in without prior GLP-1 experience, tirzepatide is typically the first-line recommendation at BHRC. The efficacy advantage is significant — an average of 5-7 additional percentage points of body weight lost — and the side effect profile is comparable to semaglutide. For patients whose primary goal is weight loss, the data strongly favors tirzepatide.

Consider semaglutide if:

• You have established cardiovascular disease — semaglutide’s SELECT trial data provides more established cardiovascular risk reduction evidence
• You previously tolerated semaglutide well and want to continue a known protocol
• You prefer an oral option — semaglutide is available in daily oral form (Rybelsus); tirzepatide is injection-only
• Cost is a significant factor — compounded semaglutide is often priced lower than tirzepatide at equivalent doses

Consider tirzepatide if:

• You want maximum weight loss — the trial data consistently shows greater results at all doses
• You have insulin resistance or metabolic syndrome — the GIP mechanism adds meaningful glycemic benefit beyond GLP-1 alone
• Previous semaglutide produced insufficient results — some patients who plateau on semaglutide respond significantly better to tirzepatide’s dual mechanism
• You’re targeting visceral fat reduction specifically — tirzepatide shows greater visceral fat loss in imaging studies

Side Effects — What to Expect on Either Protocol

Both medications share the same class of side effects because both activate GLP-1 receptors. The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most pronounced during the dose escalation phase — typically the first 8-16 weeks — and improve significantly once you reach a stable maintenance dose.

• Nausea — most common, affects ~30-40% of patients during titration. Managed with slow titration and taking the injection with food
• Vomiting — less common (10-15%), typically transient
• Diarrhea / constipation — alternating GI changes are common early; usually resolve within 4-8 weeks
• Fatigue — some patients report reduced energy during the first few weeks, usually resolving
• Injection site reactions — mild redness or swelling at injection site, resolves quickly

BHRC uses gradual titration protocols — starting at the lowest effective dose and increasing slowly — to minimize side effects. Most patients who discontinue GLP-1 therapy early do so because of poor titration, not the medication itself.

Rare but serious: Both medications carry a black box warning for thyroid C-cell tumors based on animal data (not confirmed in human clinical experience). Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use either medication.

Compounded GLP-1s in 2026 — What’s the Current Status?

Compounded semaglutide and tirzepatide have been subject to shifting FDA policy since 2024. The key driver: FDA compounding rules allow 503A and 503B pharmacies to compound drugs that appear on the FDA’s drug shortage list. Both semaglutide and tirzepatide have been on and off that list as branded supply has fluctuated.

As of mid-2026, BHRC monitors FDA compounding status continuously. We source exclusively from FDA-registered compounding pharmacies operating within current compliance guidelines. Your physician will confirm current availability and legal status at your consultation — we do not prescribe compounded medications when they fall outside compliance guidelines.

The practical takeaway: availability and pricing may change. BHRC maintains relationships with multiple compounding pharmacy partners so that protocol continuity is protected even when regulatory status shifts.

GLP-1 Therapy at BHRC — What the Protocol Looks Like

Every GLP-1 patient at BHRC starts with a free physician consultation — in person at any BHRC location or virtually. Your physician reviews your health history, current medications, labs (we order baseline metabolic panel, thyroid function, and lipids), and goals before determining whether semaglutide or tirzepatide is the right choice and at what starting dose.

• Consultation (complimentary): Health history, goals, contraindication screening, protocol recommendation
• Lab work: Baseline metabolic panel, thyroid, lipids, HbA1c (ordered at or before first visit)
• Starting dose: Always the lowest titration dose — dose escalation happens every 4 weeks based on response and tolerance
• Self-administration: Weekly subcutaneous injection at home using a pre-filled pen or vial + insulin syringe; brief training included
• Follow-up: 4-week check-ins for first 3 months; lab monitoring at 3 and 6 months
• Cost: Pricing depends on dose and titration stage — your consultation includes a full written cost breakdown. VIP Members receive 15% off all protocols.

Frequently Asked Questions